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Abstract
Background: Cervical cancer and infection with human immunodeficiency virus (HIV) are both
major public health problems in South Africa. The aim of this study was to determine the risk of
cervical pre-cancer and cancer among HIV positive women in South Africa.
Methods: Data were derived from a case-control study that examined the association between
hormonal contraceptives and invasive cervical cancer. The study was conducted in the Western
Cape (South Africa), from January 1998 to December 2001. There were 486 women with invasive
cervical cancer, 103 control women with atypical squamous cells of undetermined significance
(ASCUS), 53 with low-grade squamous intraepithelial lesions (LSIL), 50 with high-grade squamous
intraepithelial lesions (HSIL) and 1159 with normal cytology. Odds ratios (OR) and 95% confidence
intervals (CI) were calculated using multiple logistic regression.
Results: The adjusted odds ratios associated with HIV infection were: 4.4 [95% CI (2.3 – 8.4) for
ASCUS, 7.4 (3.5 – 15.7) for LSIL, 5.8 (2.4 – 13.6) for HSIL and 1.17 (0.75 – 1.85) for invasive cervical
cancer. HIV positive women were nearly 5 times more likely to have high-risk human
papillomavirus infection (HR-HPV) present compared to HIV negative women [OR 4.6 (95 % CI
2.8 – 7.5)]. Women infected with both HIV and high-risk HPV had a more than 40 fold higher risk
of SIL than women infected with neither of these viruses.
Conclusion: HIV positive women were at an increased risk of cervical pre-cancer, but did not
demonstrate an excess risk of invasive cervical cancer. An interaction between HIV and HR-HPV
infection was demonstrated. Our findings underscore the importance of developing locally relevant
screening and management guidelines for HIV positive women in South Africa.
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Background
Cervical cancer and infection with human immunodefi-
ciency virus (HIV) are both major public health problems
in South Africa. The country currently faces one of the
worst HIV epidemics in the world. In the past 15 years the
epidemic has grown exponentially, with antenatal HIV
surveillance data showing an increase in prevalence from
less than 1% in 1990 to 29.5 % in 2004 [1]. There are cur-
rently more than 5 million people with HIV/AIDS in
South Africa, with women more severely affected than
men [1].
Cancer of the cervix is the second commonest cancer
among South African women, with an age standardized
incidence rate of 30 per 100 000 per year [2]. Cervical can-
cer is included as one of the defining conditions of the
acquired immune deficiency syndrome (AIDS) [3]. Stud-
ies have shown that HIV positive women are at an
increased risk of developing cervical squamous intraepi-
thelial lesions (SIL) and cervical cancer [4-12]. In devel-
oped countries it is recommended that HIV positive
women be screened for SILs more frequently than HIV
negative women [13]. These recommendations are not
feasible in developing countries, where both HIV and cer-
vical cancer are common, and resources limited. To
develop locally feasible guidelines, data are needed on the
prevalence and risk of SILs and cervical cancer among HIV
positive women in South Africa. Here we report on one of
the first studies that provides information on the risk of
SILs among HIV positive women in the Western Cape
Province in South Africa.
Methods
Data were derived from a case-control study that exam-
ined the association between hormonal contraceptives
and invasive cervical cancer. The study was conducted in
the Western Cape from January 1998 to December 2001.
Detailed methods have been described elsewhere [14].
There were 524 cases and 1541 controls. Refusal rates
were 0.4% and 6.0 %, respectively. Cases were all Col-
oured and Black women with first occurrences of histolog-
ically confirmed invasive cervical cancer, identified at two
tertiary gynaecology oncology clinics. The terms Coloured
and Black are used to denote groups defined by race clas-
sification legislation formerly used in South Africa. In this
paper the term Black refers to African people and Col-
oured to people of mixed racial ancestry.
Nurse interviewers enrolled controls from the local Com-
munity Health Centres and the 2 tertiary hospitals. The
controls were selected to be representative of the same
population from which the cases were identified. They
were frequency-matched to the cases for decade of age,
ethnic group and area of residence at a ratio of 3:1 con-
trols per case. The trained nurse interviewers collected
data on a wide range of variables using a structured ques-
tionnaire. Papanicolaou (Pap) smears were taken from
the controls and classified according to the Bethesda sys-
tem [15]. Endocervical scrapings were taken from the con-
trols only and were assayed for human papillomavirus
(HPV) infections using the Hybrid Capture II HPV test for
the detection of high-risk HPV (HR-HPV) types. The cervi-
cal cancer cases were considered positive for HR-HPV. At
the time of the study serum samples were taken and
stored.
The study was later extended to explore the relationship
between HIV and cervical pre-cancer and cancer. Anony-
mous HIV testing was done on stored serum samples,
using the enzyme-linked immunoabsorbant assay
(ELISA). HIV data were available for 486 (93%) of the 524
cases of cervical cancer, and HIV and Pap results for 1365
(89%) of the original controls.
For the purposes of the present analysis we divided the
patients into several groups. There were 486 women with
invasive cervical cancer, 103 control women had atypical
squamous cells of undetermined significance (ASCUS),
53 had low-grade squamous intraepithelial lesions (LSIL),
50 had high-grade squamous intraepithelial lesions
(HSIL) and 1159 had normal cytology.
Written informed consent for the overall study was
obtained from all study participants. Ethical approval for
the overall study and, later, for the anonymous HIV test-
ing was granted by the University of Cape Town Research
Ethics Committee and the Boston University Ethics
Review Board.
Socio-demographic and reproductive characteristics were
examined using chi square and Kruskal-Wallis tests. The
median ages of HIV positive and HIV negative women
were compared using the Wilcoxan sign rank test. For the
association between HIV and invasive cervical cancer we
compared HIV prevalence in the cases with that in all con-
trols. For the association between HIV and SIL, women
with normal cytology were used as a reference group. Sta-
tistical analysis was carried out using unconditional mul-
tiple logistic regression (SAS version 9.1). Initial models
contained multiple variables that were considered to be
potential confounders (age, ethnic group, number of sex-
ual partners, education level, urban or rural residence,
marital status, presence of sexually transmitted infection,
number of prior Pap smears, parity, age at coitarche, alco-
hol use, tobacco use, sterilization, use of oral contracep-
tives, and use of injectable contraceptives). A backward
stepwise regression was performed. Variables were
retained in the model if they demonstrated independent
associations with the outcome of interest, or if their
removal altered the association between HIV infections
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and the outcome of interest. Systematic elimination of
variables resulted in odds ratio (OR) estimates adjusted
for age and ethnic group.
An additional analysis, which took into account joint
HIV/HR-HPV status was conducted. In this analysis
women were stratified women according to whether they
were HR-HPV positive or negative and HIV positive or
negative. In this analysis we controlled for age and ethnic-
ity.
Results
Socio-demographic and reproductive characteristics
Table 1 provides socio-demographic and reproductive
characteristic for the cases and controls for whom HIV
data was available. Cases of invasive cervical cancer were
more likely to have 4 or more sexual partners, had their
sexual debut before the age of 16 years, and smoked ciga-
rettes, and were less likely to have used hormonal contra-
ceptive and have had a prior Pap smear.
HIV and invasive cervical cancer
Overall 5.7% (78) of the HIV tested controls (1365) and
6.0% (29) of the tested cases (486) were HIV positive. The
odds ratio for the association between HIV and invasive
cervical cancer was 1.17 (95% CI 0.75 – 1.85), estimates
adjusted for age and ethnicity.
Among women with cervical cancer, those that were HIV
positive were 6 years younger that those that were HIV
negative (median age 40 years and 46 years for HIV posi-
tive and HIV negative women respectively, p = 0.004).
Overall, the majority of women with cervical cancer pre-
sented with late stage disease (stages III and IV). Analysis
of the prevalence of HIV infection according to stage of
Table 1: Socio-demographic and reproductive characteristics
Characteristic Cases (N = 486) Controls (N = 1 365) P value*
Age
< 35 years 61 (12.5) 219 (16.0)
t 35 years 425 (87.5) 1 146 (84.0) 0.065
Ethnic group
Coloured 367 (75.5) 1 030 (75.5)
Black 119 (24.5) 335 (24.4) 0.980
Residence
Rural 208 (42.8) 632 (46.3)
Urban 278 (57.2) 733 (53.7) 0.183
Marital status
Single 116 (23.9) 297 (21.8)
Married 223 (45.9) 704 (51.6)
Widowed 70 (14.4) 158 (11.6)
Divorced/separated 76 (15.6) 205 (15.0) 0.197
Sexual partners
< 4 355 (73.1) 1 105 (81.0)
t 4 127 (26.1) 252 (18.4)
Missing 4 (0.8) 8 (0.6) < 0.001
Sexual debut
< 16 years 156 (32.1) 319 (23.4)
t 16 years 318 (65.4) 1 008 (73.8)
Missing 12 (2.5) 38 (2.8) < 0.001
Hormonal contraceptive use
Never 117 (24.1) 197 (14.4)
Ever 369 (75.9) 1 168 (85.6) < 0.001
Sterilized
No 361 (74.3) 859 (62.9)
Yes 125 (25.7) 506 (37.1) < 0.001
Tobacco use
Never 159 (32.9) 550 (40.3)
Ever 326 (67.1) 815 (59.7) 0.004
Prior Pap smear
No 242 (49.8) 370 (27.1)
Yes 238 (49.0) 982 (71.9)
Missing 6 (1.2) 13 (1.0) < 0.001
* Excludes missing category
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cancer showed that 8.7% (12/138) of stage Ib and II were
HIV infected compared to 4.9% (17/346) of stage III and
IV cancers (p = 0.17).
HIV and SIL
Among the controls, 50% (39/78) of HIV positive women
had an abnormal Pap smear (20.5% ASCUS, 17.9% LSIL
and 11.5% HSIL), and 13% of the HIV negative controls
(167/1287) had an abnormal Pap smear (6.8% ASCUS,
3.0% LSIL and 3.2% HSIL). Table 2 gives the distribution
of HIV positivity in each of the groups according to cytol-
ogy. With normal women as the reference category the
adjusted odds ratios associated with HIV infection were:
ASCUS 4.4 (95% CI 2.3 – 8.4), LSIL 7.4 (95% CI 3.5 –
15.7) and HSIL 5.8 (95% CI 2.4 – 13.6).
Among women with pre-cancerous lesions, HIV positive
women tended to be younger, but the age differences were
not statistically significant for ASCUS or HSIL and only of
borderline significance for LSIL (p = 0.05).
HIV, high-risk HPV and cervical lesions
Among the controls 49% (38/78) of the HIV positive
women were positive for HR-HPV, compared to 15%
(193/1286) of the HIV negative women. HIV positive
women were almost 5 times more likely to have HR-HPV
present compared to HIV negative women [OR 4.6 (95 %
CI 2.8–7.5)]. Women infected with HIV and HR-HPV
were at a higher risk of SIL than women infected with nei-
ther of these viruses [OR 41.3; 95% CI (18.8–90.5)]
(Table 3).
Discussion
This study provides data on the risk of cervical SILs and
invasive cervical cancer among HIV positive women less
than 60 years old in the Western Cape Province in South
Africa. The extent to which HIV increases the risk for cer-
vical cancer is especially important in South Africa given
the size of the HIV epidemic. Studies have produced
inconsistent results on the association between HIV and
invasive cervical cancer [10-12]. In our study HIV positive
women did not have an excess risk of invasive cervical
cancer. This could be due to the competing risk of mortal-
ity from other conditions associated with HIV, particu-
larly in a setting where antiretroviral therapy was not
available at the time.
Similar to other studies conducted in South Africa, the
majority of women in our study, irrespective of HIV status
presented with late stage disease [16]. We found no asso-
ciation between HIV and the stage of cervical cancer. HIV
positive women with invasive cervical cancer were 6 years
younger than HIV negative women. This difference in
mean age between HIV positive and negative women is
difference in mean age is smaller than that reported in
other South African studies [16,17] and probably reflects
the earlier stage of the HIV epidemic in the Western Cape
compared to the other study sites.
Our finding that HIV infected women were at a signifi-
cantly higher risk of LSIL and HSIL confirms the findings
of studies from both developed and developing countries
[4-9,11]. The prevalence (50%) of cytological abnormali-
ties among HIV positive women is higher than has been
reported by any other study in Africa. Hawes et al reported
Table 2: HIV status and risk of SIL
N HIV positive N (%) HIV negative N (%) Adjusted OR* (95% CI)
Normal 1 159 39 (3.0) 1 120 (97.0) 1.0 (reference)
ASCUS 103 16 (15.5) 87 (84.5) 4.4 (2.3 – 8.4)
LSIL 53 14 (26.4) 39 (73.6) 7.4 (3.5 – 15.7)
HSIL 50 9 (18.0) 41 (82.0) 5.8 (2.4 – 13.6)
* OR adjusted for age and ethnicity
Table 3: HIV, HR-HPV and risk of SIL
SIL absent N SIL present N (%) Adjusted OR* (95% CI)
HIV – HR-HPV- 1 070 23 (2.1 %)) Reference
HIV+ HR-HPV- 35 5 (12.5 %) 6.5 (2.3 – 33.0)
HIV- HR-HPV+ 136 57 (29.5 %) 19.6 (11.7 – 33.0)
HIV+ HR-HPV+ 20 18 (47.4 %) 41.3 (18.8 – 90.5)
* OR adjusted for age and ethnicity
SIL absent includes Paps that were normal and had ASCUS. SIL present include LSIL and HSIL Paps.
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a cytological abnormality prevalence of 37% among
women with HIV-1 infection attending an outpatient
infectious-disease clinic in Senegal [6], Chirenje 26 %
among family planning attendants in Zimbabwe [7], Laga
27% in sex workers in Zaire [18], Maggwa 5% among fam-
ily planning attendants in Kenya [19] and Kreiss 26%
among sex workers in Kenya [20]. The controls in the case-
control study (from which our subjects were derived)
were frequency matched for age to cases of invasive cervi-
cal cancer, therefore, our study consists of slightly older
women than those in the above mentioned studies. This
difference in age could account in part for the higher prev-
alence of cervical abnormality recorded in our study.
A potential limitation of our study is that cytological
abnormalities were not histologically confirmed. How-
ever, it has been shown that the Pap smear sensitivity and
specificity are similar among HIV negative and HIV posi-
tive women [4,21]. Further, the cytologists were blinded
to HIV status and there is no reason to suspect differential
misclassification according to HIV status. Random mis-
classification would dilute the estimated effect of HIV. An
additional limitation of our study was that immune status
was not recorded. A strong association between immune
status (CD4 counts and HIV viral load) and cervical
abnormalities has been demonstrated in other studies
[5,8,9].
In developed countries it is recommended that HIV posi-
tive women have two cytological assessments within the
first year after HIV diagnosis and annually thereafter, with
referral for colposcopy for any smear showing an ASCUS
or more severe lesion [13]. These guidelines are not feasi-
ble in resource-poor settings. The high prevalence and risk
of cervical abnormalities documented in our study under-
scores the importance of developing screening and man-
agement guidelines for HIV positive women. As anti-
retroviral therapy becomes increasingly available in the
public sector in South Africa, the life expectancy of HIV
positive women will increase. It is important that this ben-
efit is not offset by an excess risk in cervical cancer. It is of
critical importance that a cervical screening program,
informed by local research on the natural history of cervi-
cal abnormalities, is in place for HIV positive women.
South Africa has recently introduced a national cervical
screening policy that all women 30 years and older are
entitled to three free Pap smears in their lifetime, at 10
year intervals [22]. Over the next few years many women
in South Africa will be screened for the first time for cervi-
cal abnormalities. According to the policy all women with
LSIL should have a repeat smear in 1 year, and all women
with HSIL referred for a colposcopy assessment. Based on
our study findings that 1 in 4 women with LSIL, and 1 in
5 women with HSIL, were HIV positive, we recommend
that every effort should be made to ensure that women
who are screened and found to have SILs should also be
offered HIV voluntary counselling and testing.
Our results are in agreement with others that have shown
an association between HIV, high-risk HPV and cervical
abnormalities [8,23]. For the combination of HIV and
HPV infection, we observed an interaction with an esti-
mated 41-fold increase in the risk of LSIL and HSIL com-
bined. This striking increase underscores the need to study
the mechanisms underlying the interaction in the patho-
genesis of cervical SIL.
Conclusion
In summary South African HIV positive women are at a
significantly increased risk of cervical HR-HPV infection
and SILs. The increased public health burden that this
poses is an important and gender-specific aspect of HIV
infection. Guidelines on how best to screen HIV positive
women for cervical abnormalities are urgently needed in
South Africa.
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